List of IBM Clinical Development Customers
Armonk, 10504, NY,
United States
Since 2010, our global team of researchers has been studying IBM Clinical Development customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased IBM Clinical Development for Clinical Trial Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using IBM Clinical Development for Clinical Trial Management include: Protrials Research, a United States based Life Sciences organisation with 190 employees and revenues of $40.0 million, iBio, Inc., a United States based Life Sciences organisation with 49 employees and revenues of $2.4 million, Oncotelic, a United States based Life Sciences organisation with 30 employees and revenues of $1.0 million and many others.
Contact us if you need a completed and verified list of companies using IBM Clinical Development, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The IBM Clinical Development customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
iBio, Inc. | Life Sciences | 49 | $2M | United States | IBM | IBM Clinical Development | Clinical Trial Management | 2020 | n/a |
In 2020, iBio, Inc. was granted 18 months of free access to IBM Clinical Development to support its COVID-19 vaccine development program. The award provisioned cloud-based Clinical Trial Management capabilities in the United States for the sponsor, enabling centralized capture and oversight of study data during the pandemic response.
iBio likely used IBM Clinical Development to implement EDC and ePRO workflows and the platform reporting capabilities to manage patient and site data. Configuration likely focused on study-specific electronic case report forms, automated data validation rules, source data reconciliation workflows, and study-level analytics to support clinical operations and data management functions.
The deployment was a cloud-hosted, sponsor-directed instance operating within the United States, aimed at supporting vaccine trial activities under a time-limited access model. Governance emphasis for this engagement would have centered on sponsor data controls, user access provisioning for clinical and data teams, and accelerated study start-up procedures to align with pandemic timelines.
|
 |
Oncotelic | Life Sciences | 30 | $1M | United States | IBM | IBM Clinical Development | Clinical Trial Management | 2020 | n/a |
In 2020, Oncotelic implemented IBM Clinical Development, a Clinical Trial Management application, to support a Phase II trial of OT-101 for COVID-19 in the United States. The selection was announced in June 2020 when Mateon granted its Oncotelic subsidiary access to IBM Clinical Development at no cost to provide cloud EDC and clinical operations capabilities for the trial.
IBM Clinical Development was provisioned as a cloud hosted clinical data platform, with configuration centered on electronic data capture workflows, inferred use of ePRO for patient reported outcomes, and remote monitoring and reporting features to support decentralized participant oversight. The implementation emphasized structured case report form design, database build for Phase II endpoints, and remote access controls consistent with clinical operations and data management practices.
Operational coverage focused on Oncotelic clinical operations and data management teams supporting the Phase II OT-101 study within the United States. Governance attention was placed on protocol aligned CRF configuration, remote monitoring workflows, and centralized reporting to coordinate site and sponsor interactions, with the system used to streamline data capture and remote patient monitoring for the clinical trial.
|
 |
Protrials Research | Life Sciences | 190 | $40M | United States | IBM | IBM Clinical Development | Clinical Trial Management | 2019 | n/a |
In 2019, ProTrials Research implemented IBM Clinical Development as a unified EDC and clinical data management platform in the Clinical Trial Management category. The deployment ran in the United States and was scoped to centralize study data and consolidate disparate EDC and paper processes into a single cloud application.
IBM Clinical Development provided electronic data capture, clinical data management capabilities, and built in randomization and trial supply management functions to support study conduct. The implementation automated start up workflows and instrumented robust audit trails through IBM Clinical Development to improve audit readiness.
Operational coverage focused on clinical data management and study start up activities for US studies, with clinical operations and data management teams using the platform for centralized study records and change control. No specific third party system integrations are documented in the source, the narrative centers on IBM Clinical Development as the single unified platform.
Governance workstreams established audit trail controls and standardized minor study change processes, and the published case study documents a reduction in the time to perform minor study changes to around 30 minutes in the United States. The configuration emphasized centralized data, automated start up tasks, and traceable change histories to support regulatory and audit workflows.
|
Buyer Intent: Companies Evaluating IBM Clinical Development
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||